Have a feature idea you'd love to see implemented?
Let us know!
EYPT EyePoint Pharmaceuticals Inc
Price (delayed)
$8.35
Market cap
$569.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.99
Enterprise value
$511.84M
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a
Highlights
EYPT's quick ratio has surged by 143% year-on-year and by 15% since the previous quarter
EYPT's gross margin is up by 10% year-on-year
The EPS has grown by 25% YoY but it has contracted by 12% from the previous quarter
EYPT's gross profit is up by 18% year-on-year but it is down by 9% since the previous quarter
The net income has declined by 19% since the previous quarter and by 3.4% year-on-year
EYPT's equity is down by 4.2% since the previous quarter
Key stats
What are the main financial stats of EYPT
Market
Valuations
Earnings
Shares outstanding
68.25M
Market cap
$569.9M
Enterprise value
$511.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.04
Price to sales (P/S)
9.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.2
Revenue
$45.71M
EBIT
-$103.49M
EBITDA
-$102.3M
Free cash flow
-$118.04M
Per share
Balance sheet
Liquidity
EPS
-$1.99
Free cash flow per share
-$2.17
Book value per share
$4.09
Revenue per share
$0.84
TBVPS
$5.53
Total assets
$300.92M
Total liabilities
$82.18M
Debt
$21.92M
Equity
$218.73M
Working capital
$219.76M
Debt to equity
0.1
Current ratio
5.5
Quick ratio
5.21
Net debt/EBITDA
0.57
Margins
Efficiency
Dividend
EBITDA margin
-223.8%
Gross margin
91.5%
Net margin
-226.6%
Operating margin
-255.9%
Return on assets
-31.6%
Return on equity
-43%
Return on invested capital
-102.7%
Return on capital employed
-41%
Return on sales
-226.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EYPT stock price
How has the EyePoint Pharmaceuticals stock price performed over time
Intraday
-6.76%
1 week
-20.4%
1 month
-21.96%
1 year
36.44%
YTD
-63.87%
QTD
4.51%
Financial performance
How have EyePoint Pharmaceuticals's revenue and profit performed over time
Revenue
$45.71M
Gross profit
$41.82M
Operating income
-$116.97M
Net income
-$103.57M
Gross margin
91.5%
Net margin
-226.6%
The net margin has declined by 32% since the previous quarter but it has increased by 3.8% year-on-year
The company's operating margin fell by 31% QoQ and by 6% YoY
The net income has declined by 19% since the previous quarter and by 3.4% year-on-year
The operating income has contracted by 19% from the previous quarter and by 14% YoY
Growth
What is EyePoint Pharmaceuticals's growth rate over time
Valuation
What is EyePoint Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.04
P/S
9.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.2
The EPS has grown by 25% YoY but it has contracted by 12% from the previous quarter
The stock's price to book (P/B) is 61% less than its 5-year quarterly average of 5.2 and 27% less than its last 4 quarters average of 2.8
EYPT's equity is down by 4.2% since the previous quarter
EYPT's P/S is 34% below its last 4 quarters average of 15.0 but 23% above its 5-year quarterly average of 8.1
The revenue has declined by 9% since the previous quarter but it has increased by 8% year-on-year
Efficiency
How efficient is EyePoint Pharmaceuticals business performance
The ROIC has soared by 74% YoY and by 48% QoQ
EyePoint Pharmaceuticals's ROE has soared by 69% YoY
EYPT's return on assets is up by 47% year-on-year but it is down by 6% since the previous quarter
The ROS has contracted by 32% from the previous quarter
Dividends
What is EYPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EYPT.
Financial health
How did EyePoint Pharmaceuticals financials performed over time
EYPT's quick ratio has surged by 143% year-on-year and by 15% since the previous quarter
EyePoint Pharmaceuticals's current ratio has soared by 134% YoY and by 16% from the previous quarter
The debt is 90% smaller than the equity
EYPT's debt to equity is up by 11% year-on-year
EYPT's equity is down by 4.2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.